LinkedIn Facebook
About Us

Our team

our-team_post our-team_post our-team_post

EyeD Pharma has a multidisciplinary team combining advanced expertise in chemistry, industrial process, pharmaceutical development, controlled release, regulatory affairs, preclinical, clinical, financial and business fields.

Our sales department also has a strong expertise (more than 20 years) in ophthalmic surgery.


PICT 1 Our managers have an average experience
of 18 years in the Pharmaceutical Industry
PICT 2 Team Growth
2021 vs 2020

Board members


CEO EyeD Pharma SA

PhD in Biomedical and Pharmaceutical sciences
(Univervity of Liège).

PhD Scientific coordinator (50 FTE) Scientific
and financial manager of an EU project.

Uteron/Mithra/Actavis, Funding coordinator in financial Department - Management of R&D program budgets.

Since 2013:
EyeD Pharma, CEO


Chairman & Co-Founder

CEO of Noshaq Spin-Off SA
Member of the Executive Committee of Noshaq Group.
CEO of B2H SA.
Investment Manager at Epimede SA.
Co-founder and past CEO of Arlenda SA.

Co-founder and Executive Chairman of Eyed Pharma SA.

Board member or Past Board member in several well-known Belgian life science scale ups (Imcyse, Mithra Pharmaceuticals, Diagenode, Hyloris, Uteron Pharma, ...)

Jean-Marie RAKIC

Board & Founding Member

Doctor in medicine since 1990 (ULg), he specialized in ophthalmology to become doctor of biomedical sciences in 1997. Specialized in vitreo-retinal surgery.

He became head of the ophthalmology department at CHU Liège in 2004 and was appointed Professor of Ophthalmology at ULg the same year.

Member of the Royal Academy of Medicine since 2014.


Board Member's Representative of NOSHAQ SA

Board member for start-ups, spin-offs and SMEs mainly for companies within the life sciences field (support in financial and strategic governance).

Master’s degree in financial management (University of Liège, Belgium).

Degrees and qualifications in international business and innovation management.


Board Member's Representative of Qbic VENTURE PARTNERS II SRL

Ph.D., MBA (Scientific and business background.

Active as a Venture Capital and Private Equity partner at Theodorus, specialized in Biotech and Med-Science spin-offs.

He accompanied numerous capital increases and has held director positions at Bone Therapeutics and Ovizio Imaging Systems.


Board Member's Representative of PIENTER-JAN SRL

Previously CFO of the Belgian biotechnology company CropDesign.

Finance Director of WorldCom/MCI Belux, and CFO and interim CEO of Keyware Technologies.

He held several financial positions at Suez Lyonnaise des Eaux and Unilever.

Currently independent board member of other companies active in life sciences such as Celyad, Bone Therapeutics, Iteos and Bioxodes. Managing partner of Fund+.

François MEURGEY

Board Member's Representative of OUKELOS SRL

Executive Director & Head-Marketing at ASIT BioTech SA.

Managing Partner at Oukelos.

He occupied the position of Senior Director-Asia-Pacific Marketing at Merck & Co., Inc. and Director-Global Marketing at Eli Lilly Benelux SA.

Graduated from Paris-Sorbonne University Abu Dhabi and an MBA from The Leonard N Stern School of Business.


Board Member

Graduated in Business (UCL-Belgium).

Big experience in retail in Europe, Asia and USA. Last position: CEO of Delhaize.

Combines executive and non-executive functions in many companies.

Focusing on start-up, scale up and SMEs mainly in retail, food and health. Chairman of finance&


Observer of OPHTALMOS

Experienced Manager with a demonstrated history of working in the management consulting industry.

Skilled in Management Consulting, Business Strategy, Sales Management, Financial Analysis, and Commercial Management.

Strong professional with a ‘Ingénieur de gestion focused in Finance et entreprenariat’ from Université de Liège.

Fund Director of White Fund SA.

Key opinion leaders

Prof. Ingeborg STALMANS

Leuven (Belgium)

Head of the Glaucoma Unit.

Belgium Director of the Laboratory
of Ophthalmology.

Prof. Keith BARTON

Moorfields Eye Hospital London (UK)

Consultant Ophthalmologist
and Glaucoma Specialist.

Honorary Reader in
UCL Institute of Ophthalmology.

Co-chair of Ophthalmology Futures Forums.

Editor-in-Chief of the British Journal
of Ophthalmology

Prof. Antonio FEA

University of Torino (Italy)

MD, PhD - Associate Prof.: Dept
of Surgical Sciences.

Part of the Editorial Board of
BMC Ophthalmology

Lead Guest Editor for J of Ophthalmology.

Author of more than 60 International peer reviewed papers.

Took part to several International Clinical Trials.

Reviewer for peer review
international journals.

Prof. Leon AU

Manchester Royal Eye Hospital (UK)

Consultant ophthalmologist.

Expert in the field of glaucoma surgeries.

Specialist advisor for the National Institute of Clinical Excellence (NICE).

Co-chairman of the associate advisory board for the International Society
of Glaucoma Surgery.


KU & UZ Leuven (Belgium)

Medicine KU Leuven : Academisch Consulent Cataract chir
& Ocular echography.

Ophthalmology UZ Leuven.

Consultant cataractsurgery and ocular ultrasound at the UZ Leuven.

Current chairman of the Belgian professional association
of ophthalmologists

Member of the European Board
of Ophthalmologists

Member of the Working Group on Extramural Ophthalmology.

Multi-speaker in Belgium and abroad.

Prof. Jean-Marie RAKIC

University Hospital of Liège (Belgium)

Doctor in medicine since 1990 (ULg).

Ophthalmologist/Dr. of biomedical sciences since 1997.

Specialized in vitreo-retinal surgery.

Head of the ophthalmology department at CHU Liège since 2004.

Professor of Ophthalmology at ULg.

Member of the Royal Academy
of Medicine
since 2014.

Prof. Nathalie COLLIGNON

University Hospital of Liège (Belgium)

Clinical Professor
of the Ophthalmology Department.

Head Chief of a Glaucoma Unit.

Treasurer of Belgian Glaucoma society.

Board member of the
French Glaucoma Society

Our values

Patient Driven

All our product candidates aim to enhance patient quality of life and are based on clinical unmet need identified by internationally renowned KOL’s

Patient Driven
Breakthrough Innovation

We manage all the expertise and processes, from the idea to the market

Breakthrough Innovation
Corporate Responsibility

Creation of high-quality long-term employment and significant contribution to the economic redeployment of Wallonia. Eyed’s team is today composed of 66 FTEs

Corporate Responsibility
Humanitarian Mission

Our technological platform allows to give access to long term innovative ophthalmological treatments to developing countries populations, where glaucoma is the second cause of blindness

Humanitarian Mission